Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22323630 | 0.89 | GSR (0.43) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL5932816 | 0.87 | GSR (0.42) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL4441195 | 0.86 | GSR (0.39) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL258789 | 0.85 | GSR (0.41) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL3299147 | 0.85 | ALDH1A1 (0.49) | GSRCYP2D6SRCKMT2AALDH1A1 | |
| SCHEMBL38107 | 0.85 | NPSR1 (0.43) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL5932183 | 0.85 | GSR (0.41) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL10640253 | 0.85 | GSR (0.41) | GSRCYP2D6SRCLMNAMAPK1 | |
| SCHEMBL4277062 | 0.84 | TSHR (0.50) | GSRLMNAMAPK1KMT2ACES2 | |
| SCHEMBL27847496 | 0.84 | KMT2A (0.46) | GSRKMT2AALDH1A1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 667 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119350283-A | Prazomycin impurity H and preparation method thereof | 上海上药新亚药业有限公司 | 2025-01-24 | — | — | CN | claimed |
| CN-105555759-A | Compounds with antibacterial activity | FUND MEDINA CT DE EXCELENCIA EN INVESTIG DE MEDICAMENTOS INNOVADORES EN ANDALUCIA | 2016-05-04 | — | — | CN | claimed |
| WO-2005058246-A2 | METHOD FOR PREPARING RADIOLABELED THYMIDINE | MOLECULAR TECHNOLOGIES, INC. (US) | 2005-06-30 | — | — | WO | claimed |
| WO-2026089784-A2 | COMPOUNDS AND COMPOSITIONS FOR CONJUGATION TO BIOLIGANDS FOR IMAGING AND RADIOPHARMACEUTICAL APPLICATIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4667537-A1 | PRIMER COMPOSITION, LAMINATE, AND METHOD FOR PRODUCING LAMINATE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2025-12-24 | — | — | EP | disclosed |
| US-20250382500-A1 | PRIMER COMPOSITION, LAMINATE, AND METHOD FOR PRODUCING LAMINATE | TOKYO OHKA KOGYO CO LTD (JP) | 2025-12-18 | — | — | US | disclosed |
| US-20250271751-A1 | PHOTOSENSITIVE COMPOSITION, PHOTOSENSITIVE FILM, LOWER LAYER FILM, METHOD FOR PRODUCING STRUCTURE HAVING PHASE-SEPARATED STRUCTURE, AND COMPOUND | TOKYO OHKA KOGYO CO., LTD. (JP) | 2025-08-28 | — | — | US | disclosed |
| US-20250189895-A1 | METHOD OF MANUFACTURING PLATED ARTICLE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2025-06-12 | — | — | US | disclosed |
| CN-120065622-A | Photosensitive resin composition and method for producing microlens | 东京应化工业株式会社 | 2025-05-30 | — | — | CN | disclosed |
| US-20250172872-A1 | CHEMICALLY AMPLIFIED POSITIVE-TYPE PHOTOSENSITIVE COMPOSITION, METHOD OF MANUFACTURING SUBSTRATE WITH TEMPLATE, AND METHOD OF MANUFACTURING PLATED ARTICLE | TOKYO OHKA KOGYO CO., LTD. (JP) | 2025-05-29 | — | — | US | disclosed |
| US-12281126-B2 | Inhibitors of cyclin-dependent kinase 7 and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| WO-2001096336-A2 | 6,5-FUSED BICYCLIC HETEROCYCLES | WARNER-LAMBERT COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000056925-A2 | METHODS FOR SINGLE NUCLEOTIDE POLYMORPHISM DETECTION | ACLARA BIOSCIENCES, INC. (US) | 2000-09-28 | — | — | WO | disclosed |
| US-5908926-A | 5'to 3' nucleic acid synthesis using 3'-photoremovable protecting group | DUKE UNIVERSITY (US) | 1999-06-01 | — | — | US | disclosed |
| EP-0815114-A4 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | UNIV DUKE (US) | 1999-02-24 | — | — | EP | disclosed |
| US-5721099-A | Complex combinatorial chemical libraries encoded with tags | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0815114-A1 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | DUKE UNIVERSITY (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997026873-A1 | ANTIMICROBIAL AURONE DERIVATIVES | PHYTERA, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1996028457-A1 | NUCLEIC ACID SYNTHESIS USING PHOTOREMOVABLE PROTECTING GROUPS | DUKE UNIVERSITY (US) | 1996-09-19 | — | — | WO | disclosed |
| EP-0114341-B1 | DYE-CONTAINING LAYER IN A PHOTOPOLYMERISABLE COMPOSITION, AND PROCESS FOR OBTAINING RELIEF AND PRINTING FORMES | BASF Aktiengesellschaft (DE) | 1991-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12281126-B2 | Inhibitors of cyclin-dependent kinase 7 and uses thereof | CDK9, CDK7, CDK1 | GSR 3140/4885CYP2D6 1280/4885SRC 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.